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Abstract
Background: Recent advances in understanding complex tumor interactions have led to the discovery of an
association between inflammation and cancer, in particular for colon and lung cancer, but only a very few have
dealt with oral cancer. Therefore, the aim of the current study was to investigate the significance of preoperative
C-reactive protein (CRP) levels as a parameter for development of lymph node metastases or recurrence.
Materials and methods: In 278 patients with oral cancer, preoperative CRP levels were compared with
development of recurrence and metastasis.
Results: In 27 patients from the normal CRP group, and in 21 patients from the elevated CRP group, local
recurrence was observed. Concerning lymph node metastases, 37 patients were in the normal group and
9 patients in the elevated CRP group. No significant correlation could be found between elevated CRP levels
and metastasis (p = 0.468) or recurrence (p = 0.137).
Conclusion: Our findings do not appear to support a correlation between preoperative CRP levels and
development of recurrence or metastases. In further studies, CRP levels in precancerous lesions and in Human
Papilloma Virus (HPV) positive patients with oral squamous cell carcinoma (SCC) should be studied.
Introduction
In 1863, Rudolf Virchow postulated the induction
hypothesis that cancer originated at site of chronic
inflammation [1]. Chronic inflammation is associated
with the risk of cancer. For instance, human immuno-
deficiency virus, viral hepatitis B, and human papilloma
virus are well known for their association with an
increased risk of cancer [1]. An argument for the
hypothesis that inflammation is associated with cancer
is also derived from the reduced risk for colorectal
cancer that has been associated with long-term use of
aspirin and other nonsteroidal anti-inflammatory
drugs [2].
C-reactive protein (CRP) is an acute-phase protein and
a marker for inflammation. The synthesis of CRP in the
hepatocytes may be regulated by pro-inflammatory cyto-
kines like interleukin-1, interleukin-6, and tumor-necro-
sis factor, which are also reported for different
malignancies. Therefore, these pro-inflammatory cyto-
kines are currently the subject of intense studies as
influencing factors in various types of tumors. It is
increasingly recognized that in addition to tumor stage,
the disease progression depends on a complex interac-
tion between the tumor and the host’si n f l a m m a t o r y
response.
Two hypotheses could be associated with increased
CRP levels as a sign of chronic inflammation. First, the
induction hypothesis: chronic inflammation results in
excessive cell proliferation and activation of a cascade of
cellular actions, leading to induction of irreversible
D N Ad a m a g e[ 1 ] .S e c o n d ,t h er e s p o n s eh y p o t h e s i s :t h e
immune response of the host as a consequence of
tumor growth itself could be the reason for the elevation
in CRP levels [3]. However, it is still unclear whether
CRP levels are elevated before the biological onset of
cancer or if an elevated CRP level is also a risk factor
for the development of cancer.
Findings from the studies, however, have been incon-
sistent. Some authors have observed an association
between elevated serum CRP levels in some cancers,
like colorectal [4-6] and lung [2]. On the other hand,
some researchers doubt that CRP can be regarded
as a prognostic marker [7]. However, raised CRP
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tor of a poorer prognosis for squamous cell carcinoma
(SCC) in patients with esophageal cancer [8,9], but con-
cerning the cancer of the oral cavity only a very few stu-
dies have dealt with this topic so far (Table 1). All of
these data are consistent with the hypothesis that CRP
levels increase after onset of oral cancer.
Therefore, the aim of the current study was to investi-
gate the significance of preoperative CRP levels as a
parameter for development of lymph node metastases or
recurrence.
Materials and methods
Chosen for evaluation were 278 patients (119 female,
159 male) with oral SCC that were treated between
1999 and 2008 at a single center (Department of Cra-
niomaxillofacial and Oral Surgery, University Hospital
Zurich). All serum CRP levels (obtained between one
and 5 days prior to surgical treatment), recurrence rate,
and lymph node metastases were taken into considera-
tion. The minimum follow-up time was 12 months.
Exclusion criteria were inadequate information and a
follow-up time of less than 12 months.
The patients were divided into two groups according
to the preoperative measure of C-reactive protein
concentration: those with CRP values in the normal
range (< = 5.0 mg/L), and those with elevated RP levels
(>5.0 mg/L) according to Khandavilli et al. [12] and
Komai et al. [13].
For statistical analysis SPPS 18 (SPSS Inc, Chicago, IL)
for the Mac was used. P value < 0.05 was considered to
be statistically significant. Kaplan-Meier analysis with
log-rank testing was used for univariate analysis.
Results
Out of 278 patients with a mean CRP of 7.36 mg/L, 193
(69.4%) patients had a preoperative CRP level < = 5 mg/
L; 85 (30.6%) patients had a CRP level >5 mg/L; and the
distribution was independent of age (Fig. 1).
Local recurrence was seen in 48 patients (17.3%), with
a mean time of 24.31 months (range: 7-84 months); 2cd
tumors in 24 (8.6%); and no recurrence in 206 (74.1%).
Cervical lymph node metastases were observed in 46
patients (16.5%) after a mean time of 18.27 months
(range: 4-71 months), distant metastases in 14 (5%), and
no metastases in 218 patients (78.5%).
It was striking that although recurrence appeared ear-
lier in the elevated CRP group (Fig. 2), no difference
was found concerning the time of metastases (Fig. 3).
In 27 patients in the normal CRP group and in
21 patients belonging to the elevated CRP group, local
recurrence was observed. Concerning lymph node
metastases, 37 patients were in the normal group and
9 patients in the elevated CRP. No significant correla-
tion was found neither for development of metastasis
(p = 0.468) (Fig. 4) nor for recurrence (p = 0.137) (Fig. 5).
Table 1 Studies dealing with the association between oral SCC and preoperative CRP levels
Author Number of patients Results
Gallo et al. [10] 18 Significance of CRP and IL-6 in regard to tumour stage
Jablonska et al. [11] 42 CRP, IL-1b, IL-6, TNF-a serum levels related to clinical stage of disease
Khandavilli et al. [12] 60 CRP level is associated with worse overall outcome
Figure 1 Distribution of age and CRP.
Figure 2 Distribution of time to recurrence dependent on CRP
level.
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In order to establish prognostic predictors for oral SCC,
several studies have been performed. The purpose of
our study was to find a simple and cost effective indica-
tor for oral SCC. The mean follow-up time was 35.97
months (range: 12-107 months).
In this study, the mean value of serum CRP was 7.36
mg/L; the serum level was raised in 85 patients (30.6%);
the increase was mostly moderate (Fig. 1); and a high
increase of more than 50 mg/L, seen in infectious disease,
was found in 6 patients. The proportion of lymph node
metastasis in the group of elevated CRP levels was smaller
than that in the patients without CRP elevation. But no
significant association between raised CRP levels and
development of recurrence or metastases could be seen.
Therefore this study does not confirm the results from
other studies (Table 1) and we also disagree with Zingg U
et al. [14] who suggested CRP-measurements in the re-sta-
ging process in patients who have undergone neoadjuvant
treatment for esophageal cancer in order to help to select
patients who are likely to benefit from surgery.
In the literature there seems to be inconsistency con-
cerning the CRP levels: some authors have described
CRP levels of more than 5 mg/L as raised (13, 14), while
others have considered a more precise differentiation
into three groups: low (<1 mg/L), average (1.0 - 3.0 mg/
L), and high (>3.0 mg/L). In the current study, a CRP
level of more than 5 mg/L was considered as raised. But
one has to keep in mind that CRP levels can be reduced
with smoking cessation [15] and weight loss[16,17].
Patients with cancer of the oral cavity can be in poor
nutritional condition. For esophageal cancer, a correla-
tion has been shown between elevated serum CRP con-
centration and malnutrition with impaired immunity
[9]. Furthermore, smoking and alcohol abuse can also
lead to chronic inflammation in the oral mucosa. There-
fore, it would be of interest to investigate CRP levels in
precancerous lesions–e. g., erosive lichen. Ki et al. [18]
reported a significant correlation between the presence
of acute mucositis and CRP level in 40 patients during
radiotherapy for primary laryngo-pharyngeal cancer.
A strength of the current study was the high number
of patients. One limitation is that CRP was measured at
one point in time. Therefore intraindividual variations
were not considered. Furthermore, general diseases asso-
ciated with possible higher inflammation markers like
diabetes mellitus or Morbus Crohn were not taken into
consideration due to lack of informations.
However, CRP is a nonspecific marker of inflamma-
tion, and additional studies of specific cytokines that
regulate acute-phase response are necessary to elucidate
t h em e c h a n i s m sb yw h i c hi n f l ammation influences the
risk of cancer.
Figure 3 Distribution of time to metastases dependent on CRP
level.
Figure 4 Kaplan-Meier analysis of development of metastasis
in regard to CRP level.
Figure 5 Kaplan-Meier analysis of development of recurrence
in regard to CRP level.
Kruse et al. Head & Neck Oncology 2010, 2:21
http://www.headandneckoncology.org/content/2/1/21
Page 3 of 4Conclusion
In summary, our findings do not appear to support a
positive association between preoperative CRP levels
and oral SCC. Further studies should examine CRP
levels in precancerous lesions and in HPV positive
patients with oral SCC.
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